Congratulations to the authors on their #NARCANCER publication! 🎉 Deleterious #SMC5/6 variants may predict higher #tumormutationalburden and better responses to #immunotherapy, highlighting their potential as #biomarkers for #precisioncancertherapy.
Bill Dynan - NAR Cancer EditorCan SMC5/6 status help guide precision cancer therapy? A new NAR Cancer study links deleterious SMC5/6 variants to tumor mutational burden and immunotherapy responses, driven via POLE dysfunction and mismatch repair deficiency.https://academic.oup.com/narcancer/article/8/2/zcag012/8688771